NOVAVAX to Present at Stifel Nicolaus Healthcare Conference
ROCKVILLE, Md., Sep 6, 2011 (GlobeNewswire via COMTEX) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer of Novavax, will be presenting at the Stifel Nicolaus Healthcare Conference on September 8, 2011 at 10:20am at the Four Seasons Hotel in Boston, Massachusetts. A live audio-only webcast link for the presentation can be accessed via the company website at www.novavax.com under Investors/Events.
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Novavax, Inc.
CONTACT: Frederick W. Driscoll VP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000